<DOC>
	<DOCNO>NCT00636285</DOCNO>
	<brief_summary>The purpose Phase 1 study evaluate safety pharmacokinetics BSYX-A110 small number healthy adult volunteer . Following demonstration safety adult , anti-Staphylococcal monoclonal antibody evaluate target population hospitalize low birth weight neonate .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study Adults Prevention S. Epidermidis Infection Low Birth Weight Infants</brief_title>
	<detailed_description>This study evaluate safety three dose BSYX-A110 adult initiate study target population low birth weight infant . This open label , dose-ranging study BSYX-A110 12 adult . The dose level evaluate 3 , 10 20 mg/kg . Each dose level enroll 4 adult volunteer receive one dose BSYX-A110 intravenously . The primary endpoint study safety tolerability . The secondary endpoint include pharmacokinetics rise anti-LTA antibody opsonic activity S. epidermidis .</detailed_description>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Subjects must 18 year age old . 2 . Subjects must good general health , without significant medical history , physical examination finding clinical laboratory abnormality . 3 . Negative screen pretreatment pregnancy test female subject . 4 . Subjects childbearing potential must agree use acceptable method contraception throughout course study . 5 . All aspect protocol explain write informed consent obtain . 1 . Known suspected immunodeficiency ( e.g . HIV infection , significant risk factor HIV , primary immunosuppressive disorder ) , use immunosuppressive antineoplastic drug except corticosteroid use indication immunosuppression . 2 . Clinically significant laboratory abnormality ( great 1.5 upper limit normal. ) . 3 . Serology positive HIV , hepatitis B surface antigen hepatitis C antibody . 4 . History leukemia , lymphoma malignancy . 5 . Clinically significant cardiac , respiratory , renal , hepatic , neurological disorder 6 . Pregnant lactating female ( woman childbearing potential undergo pregnancy test ) . 7 . Receipt vaccine within 30 day . 8 . History drug alcohol dependence , significant acute chronic medical psychiatric illness would limit subject 's ability complete study and/or compromise objective study . 9 . Fever acute illness within 3 day prior treatment . ( These subject reschedule treatment later date ) . 10 . Participation another investigational drug vaccine trial within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>A110</keyword>
	<keyword>Safety</keyword>
</DOC>